Novartis announced that Scemblix has been granted priority review status by the Food and Drug Administration for treatment of newly diagnosed adult patients with Philadelphia chromosome-positive chronic Myeloid leukemia in chronic phase.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS: